JPRN-UMIN000005703已完成2 期
Randomized phase II study of sorafenib and hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma. - HCC_Sor_CDDP_rP2
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 105
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Refractory pleural effusion or ascites 2) Encephalopacy 3) Concurrent disease a) Serious hypertension b) Severe heart disease c) Acute myocardial infarction within 6 months orior to inclusion d) Active double cancer e) Severe mental disorder f) Allergic reaction to iodine contrast material g) Severe drug allergy 4) Pregnant and lactating females; females of childbearing age unless using effective contraception 5) Inadequate for administration orally 6) Concomitant treatment with drugs inductors of CYP3A4 7) Inadequate physical condition,as diagnosed by primary physician
研究者
相似试验
进行中（未招募）
1 期
A randomized phase II trial assessing Sorafenib (Nexavar®) in combination with irinotecan in metastatic colorectal cancer patients with KRAS mutated tumours after failure of all active drugs known to be effective. - NEXIRI 2metastatic colorectal cancerMedDRA version: 16.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2012-000644-94-FRCentre Val d’Aurelle - Paul Lamarque159
招募中
2 期
Phase II study of sorafenib-regorafneib sequential therapy for the patients with advanced hepatocellular carcinoma previously treated with lenvatinibHepatocellular carcinomaJPRN-jRCT1041190082Yamashita Tatsuya33
已完成
1 期
The effect of Sorafenib and intermittent hepatic arterial infusion chemotherapy using Cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus : a phase 1 studyAdvanced hepatocellular carcinomaJPRN-UMIN000004107Kansai Medical University Hirakata Hospital18
进行中（未招募）
1 期
A Phase 2 study of Sorafenib (BAY 43-9006) in patients with advanced salivary Adenoid Cystic CarcinomaEUCTR2008-000066-22-GBChristie Hospital NHS Foundation Trust
已完成
不适用
Pilot Study of the combination of sorafenib and fractionated irinotecan in pediatric relapse/refractory hepatic cancerJPRN-UMIN000021931Kanagawa children's medical center12